Targeting Dopaminergic Pathways: Current and Emerging Dopamine Inhibitors in Neurological and Psychiatric Disorders - PubMed
3 hours ago
- #Neuropsychiatric disorders
- #Nanotechnology
- #Dopamine inhibitors
- Dopaminergic signaling is crucial for motor control, reward processing, and emotional balance.
- Dysregulation of dopamine pathways is linked to various neuropsychiatric disorders.
- Current dopamine inhibitors include receptor antagonists, transporter blockers, and indirect modulators.
- Antipsychotics are key in schizophrenia treatment, while dopamine transporter inhibitors like methylphenidate are first-line for ADHD.
- Monoamine oxidase inhibitors are important in Parkinson's disease management.
- Long-term use of dopaminergic agents can cause extrapyramidal symptoms and metabolic disturbances.
- Recent advances include subtype-selective modulators, nanotechnology-based delivery, and combination therapies.
- Challenges include side effects and poor receptor selectivity.
- Emerging strategies like targeted delivery and personalized treatments aim to improve efficacy and tolerability.